Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice TargetHot
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $922 to $1175.
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $922 to $1175.